Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Eli Lilly boosts revenue guidance for 2021 and issues an outlook for 2022.

Eli Lilly Boosts 2021 Guidance and Issues a Strong 2022 Forecast. The Stock Jumps.

Eli Lilly raised its full-year 2021 profit and sales forecast on Wednesday, helped partly by a recent U.S. government contract for its COVID-19 antibody treatment.

Eli Lilly raises 2021 profit forecast

Eli Lilly & Co. shares LLY, +0.34% rose 5% in premarket trade Wednesday, after the company raised guidance as part of an update on its pipeline released ahead of an investor day. The company said it now expects 2021 adjusted per-share earnings of $8.15 to $8.20 on revenue of $28.0 billion to $28.3 billion.

Eli Lilly shares jump 5% premarket after company raises guidance in update on pipeline

INDIANAPOLIS, Dec. 15, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) is providing extensive updates across its research and development (R&D) programs to highlight the company's strong pipeline and potential for future growth. At an investment community meeting today, the company is sharing key information across its four therapeutic areas – including pipeline updates and future R&D investments – along with 2022 financial guidance and updated 2021 guidance.

Lilly Highlights Innovation-based Growth Strategy and Pipeline Developments; Announces 2022 Financial Guidance at Investment Community Meeting

INDIANAPOLIS, Dec. 14, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that mirikizumab met the primary endpoint of clinical remission and all key secondary endpoints at one year in LUCENT-2, a Phase 3 maintenance study evaluating the efficacy and safety of mirikizumab for the treatment of patients with moderately-to-severely active ulcerative colitis (UC). Patients in this study were previously enrolled in a 12-week induction study, LUCENT-1.

Mirikizumab Demonstrates Superiority over Placebo in Phase 3 Maintenance Study in Ulcerative Colitis, Supporting Regulatory Submissions in 2022

Already a leader in diabetes treatments, Eli Lilly and Co. ( LLY , Financial) last week made a move to strengthen its market position by signing a multiyear collaborative partnership with China's Regor Therapeutics Group. Under the pact, which could be worth more than $1.5 billion to the three-year-old Regor, the companies will work together to develop new therapies for diabetes and other metabolic disorders, including obesity, and nonalcoholic steatohepatitis.

Eli Lilly Strikes Deal With Chinese Company on New Drugs for Diabetes

Pfizer

PFE vs. LLY: Which Stock Is the Better Value Option?

PFE vs. LLY: Which Stock Should Value Investors Buy Now?

Foghorn (FHTX) soars following a collaboration with pharma giant Lilly for novel oncology targets.

Foghorn (FHTX) Surges on Oncology Collaboration With Lilly

Fortune Brands Home & Security

Trinity Industries

After years of a low interest rate environment, many investors have turned to equities not only for the growth potential but also for solid and dependable dividends, which help to provide an income stream.

4 ‘Strong Buy' Rated Stocks With Expected Dividend Hikes This Week

Eli Lilly And Co (NYSE: LLY) announced a 15% increase in its quarterly dividend. These are the details.

Eli Lilly Stock (LLY): 15% Increase In Quarterly Dividend Announced

Eli Lilly (LLY) closed the most recent trading day at $248.53, moving +1.8% from the previous trading session.

Eli Lilly (LLY) Gains As Market Dips: What You Should Know

Eli Lilly & Co. LLY, +1.90% said Monday that its board hiked its dividend by 15%. The drug maker said the 98-cents-a-share dividend will be paid to shareholders of record as of Feb. 15 on March 10.

Eli Lilly hikes quarterly dividend 15%

INDIANAPOLIS, Dec. 13, 2021 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has announced a 15 percent increase in its quarterly dividend and declared a dividend for the first quarter of 2022 of $0.98 per share on outstanding common stock. The dividend is payable on March 10, 2022 to shareholders of record at the close of business on Feb. 15, 2022.

Lilly Announces 15 Percent Dividend Increase, First-Quarter 2022 Dividend

Lilly (LLY) inks a strategic collaboration with Regor Therapeutics to discover and develop novel therapies for metabolic disorders.

Lilly (LLY) Inks Metabolic Disorders Therapy Development Deal

Foghorn Therapeutics

Loxo Oncology, an R&D group of Eli Lilly And Co (NYSE: LLY), and Foghorn Therapeutics Inc (NASDAQ: FHTX) have collaborated to create oncology medicines by applying Foghorn's Gene Traffic Control platform.  The collaboration includes a co-development and co-commercialization agreement for Foghorn's selective BRM oncology program and an additional undisclosed oncology target.

Foghorn Therapeutics Stock Surges After $1.5B Cancer Pact With Eli Lilly

Eli Lilly & Co. LLY, +0.51% said Monday it has entered a strategic collaboration with Foghorn Therapeutics Inc. FHTX, +4.26% for novel oncology targets using Foghorn's proprietary gene traffic control platform, a move that sent Foghorn's shares up 26% in premarket trading. As part of the deal, Eli Lilly will pay $300 million upfront and make an equity investment in Foghorn of $80 million, priced at $20 a share.

Foghorn Therapeutics shares soar 26% premarket on news of cancer collaboration with Eli Lilly

INDIANAPOLIS and CAMBRIDGE, Mass. , Dec. 13, 2021 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Foghorn Therapeutics Inc. (Nasdaq: FHTX), today announced a strategic collaboration to create novel oncology medicines by applying Foghorn's proprietary Gene Traffic Control ® platform.

Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn's Proprietary Gene Traffic Control® Platform

INDIANAPOLIS, Dec. 12, 2021 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), today announced updated clinical data from the pirtobrutinib global Phase 1/2 BRUIN clinical trial in patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and mantle cell lymphoma (MCL). Pirtobrutinib is an investigational, highly selective, non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor.

Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for Pirtobrutinib at the American Society of Hematology Annual Meeting

Intuitive Surgical

Both companies look promising, but they are a bit expensive.

2 Stocks to Buy if There Is a Market Crash

The Fed decision and an Eli Lilly update are the big events on our radar next week.

Cramer's Investing Club: What we are watching next week, including the Fed and an Eli Lilly update

Eli Lilly And Co (NYSE: LLY) is making a $1.5 billion biobucks bet on Chinese biotech Regor Therapeutics to develop new therapies for metabolic disorders. Under the deal, Lilly will have a license to select Regor IP with an option to extend the license.

Eli Lilly Pens $1.5B Pact With Regor For Metabolic Disease Therapies

INDIANAPOLIS and SHANGHAI, Dec. 10, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Regor Therapeutics Group have entered into a multi-year research collaboration and licensing agreement to discover, develop and commercialize novel therapies for metabolic disorders. Under the terms of the agreement, Lilly will have a license to select Regor intellectual property with an option to extend the license.

Lilly and Regor Therapeutics Group Enter into Strategic Collaboration to Discover and Develop Novel Therapies for Metabolic Disorders

INDIANAPOLIS, Dec. 9, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced results from the CONFIDE Study (Communicating Needs and Features of IBD Experiences) that show bowel urgency – defined as the sudden or immediate need for a bowel movement – is the second most commonly reported symptom suffered by study respondents living with moderately-to-severely active ulcerative colitis (UC), regardless of whether or not they were receiving an advanced therapy (biologic or novel oral therapy). In this study, only one in four healthcare providers perceived bowel urgency as one of the top three most reported symptoms by their patients.

New Lilly Study Reveals Underappreciation of Bowel Urgency as a Symptom of Ulcerative Colitis and Highlights Communication Gap Between Healthcare Providers and Patients

Eli Lilly & Company ( LLY , Financial) is a pharmaceutical giant based in the United States that specializes in the discovery, development, manufacture and sale of various pharmaceutical products. Lilly was the company that introduced Iletin, the world's first commercially available insulin medication for the treatment of diabetes, and it was also the first company to manufacture and distribute Jonas Salk's polio vaccine.

Eli Lilly's Pipeline Strength Paints a Promising Outlook

With the approval in children and infants, Lilly's (LLY) bamlanivimab with etesevimab can now be given as treatment and prevention options to high-risk individuals of any age.

News for Eli Lilly Stock (LLY)